Scholarlink

<p>Chagas disease, caused by <i>Trypanosoma cruzi</i>, is a vector-borne parasitic disease, and dogs are a major domestic host of the parasite. We performed the first randomized field trial of an immunotherapeutic vaccine among client-owned dogs with natural infections and investigated immune correlates of efficacy. Thirty one dogs with <i>T. cruzi</i> infection received three doses of Tc24-C4 and TSA1-C4 recombinant proteins with MPLA (<i>N</i> = 16) or saline control (<i>N</i> = 15) and were followed for six months. Therapeutic vaccination decreased parasite burden, prevented/stopped cardiac alterations measured by electrocardiographic (ECG) recordings and was safe. Vaccine treatment induced changes in T cell activation and T cell receptor (TCR) repertoire, and also inhibited the ongoing innate immune response to reduce inflammation, suggesting a complex interplay between innate and T cells. These results support the further development of a vaccine based on these antigens to prevent the progression of chronic cardiac disease from <i>T. cruzi</i> infection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Randomized field trial of a therapeutic vaccine against Trypanosoma cruzi natural infection in dogs and correlates for efficacy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月18日

查看全文
  • Jorge A. Calderón-Quintal,
  • Christian F. Teh-Poot,
  • Landy M. Pech-Pisté,
  • Pedro P. Martinez-Vega,
  • Victor Dzul-Huchim,
  • Juan Felipe Torres-Acosta,
  • Etienne Waleckx,
  • Liliana Villanueva-Lizama,
  • Jaime Ortega-Lopez,
  • Claudia Herrera,
  • Eric Dumonteil,
  • Julio Vladimir Cruz-Chan

摘要

Chagas disease, caused by Trypanosoma cruzi, is a vector-borne parasitic disease, and dogs are a major domestic host of the parasite. We performed the first randomized field trial of an immunotherapeutic vaccine among client-owned dogs with natural infections and investigated immune correlates of efficacy. Thirty one dogs with T. cruzi infection received three doses of Tc24-C4 and TSA1-C4 recombinant proteins with MPLA (N = 16) or saline control (N = 15) and were followed for six months. Therapeutic vaccination decreased parasite burden, prevented/stopped cardiac alterations measured by electrocardiographic (ECG) recordings and was safe. Vaccine treatment induced changes in T cell activation and T cell receptor (TCR) repertoire, and also inhibited the ongoing innate immune response to reduce inflammation, suggesting a complex interplay between innate and T cells. These results support the further development of a vaccine based on these antigens to prevent the progression of chronic cardiac disease from T. cruzi infection.